273 related articles for article (PubMed ID: 35228898)
1. Pyroptosis-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with UCEC.
Liu J; Geng R; Ni S; Cai L; Yang S; Shao F; Bai J
Mol Ther Nucleic Acids; 2022 Mar; 27():1036-1055. PubMed ID: 35228898
[TBL] [Abstract][Full Text] [Related]
2. Inflammation-Related LncRNAs Signature for Prognosis and Immune Response Evaluation in Uterine Corpus Endometrial Carcinoma.
Gu H; Song J; Chen Y; Wang Y; Tan X; Zhao H
Front Oncol; 2022; 12():923641. PubMed ID: 35719911
[TBL] [Abstract][Full Text] [Related]
3. Cuproptosis-Associated lncRNA Gene Signature Establishes New Prognostic Profile and Predicts Immunotherapy Response in Endometrial Carcinoma.
Jiang XY; Hu JJ; Wang R; Zhang WY; Jin QQ; Yang YT; Mei J; Hong L; Yao H; Tao F; Li JJ; Liu Y; Zhang L; Chen SX; Chen G; Song Y; Zhou SG
Biochem Genet; 2023 Dec; ():. PubMed ID: 38108937
[TBL] [Abstract][Full Text] [Related]
4. Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma.
Liu J; Geng R; Yang S; Shao F; Zhong Z; Yang M; Ni S; Cai L; Bai J
Front Immunol; 2021; 12():788431. PubMed ID: 34970268
[TBL] [Abstract][Full Text] [Related]
5. Development of an Oxidative Phosphorylation-Related and Immune Microenvironment Prognostic Signature in Uterine Corpus Endometrial Carcinoma.
Liu J; Chen T; Yang M; Zhong Z; Ni S; Yang S; Shao F; Cai L; Bai J; Yu H
Front Cell Dev Biol; 2021; 9():753004. PubMed ID: 34901000
[No Abstract] [Full Text] [Related]
6. Identification of Five m6A-Related lncRNA Genes as Prognostic Markers for Endometrial Cancer Based on TCGA Database.
Shan L; Lu Y; Xiang CC; Zhu X; Zuo ED; Cheng X
J Immunol Res; 2022; 2022():2547029. PubMed ID: 35571565
[TBL] [Abstract][Full Text] [Related]
7. N1-Methyladenosine-Related lncRNAs Are Potential Biomarkers for Predicting Prognosis and Immune Response in Uterine Corpus Endometrial Carcinoma.
Liu J; Geng R; Zhong Z; Zhang Y; Ni S; Liu W; Du M; Bai J
Oxid Med Cell Longev; 2022; 2022():2754836. PubMed ID: 35965688
[TBL] [Abstract][Full Text] [Related]
8. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
[TBL] [Abstract][Full Text] [Related]
9. Identification of an Immune-Related LncRNA Prognostic Signature in Uterine Corpus Endometrial Carcinoma Patients.
Sun XX; Wen HQ; Zhan BX; Yang P
Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758230
[TBL] [Abstract][Full Text] [Related]
10. Machine learning combined with single-cell analysis reveals predictive capacity and immunotherapy response of T cell exhaustion-associated lncRNAs in uterine corpus endometrial carcinoma.
Jiang F; Tao Z; Zhang Y; Xie X; Bao Y; Hu Y; Ding J; Wu C
Cell Signal; 2024 May; 117():111077. PubMed ID: 38311301
[TBL] [Abstract][Full Text] [Related]
11. Endoplasmic reticulum stress related IncRNA signature predicts the prognosis and immune response evaluation of uterine corpus endometrial carcinoma.
Chen J; Shen L; Yang Y
Front Oncol; 2022; 12():1064223. PubMed ID: 36686816
[TBL] [Abstract][Full Text] [Related]
12. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
Chen Y
Front Genet; 2022; 13():912037. PubMed ID: 35937995
[No Abstract] [Full Text] [Related]
13. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.
Wang Z; Xing L; Huang Y; Han P
Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126
[TBL] [Abstract][Full Text] [Related]
14. MiRNA based tumor mutation burden diagnostic and prognostic prediction models for endometrial cancer.
Lu N; Liu J; Ji C; Wang Y; Wu Z; Yuan S; Xing Y; Diao F
Bioengineered; 2021 Dec; 12(1):3603-3620. PubMed ID: 34252354
[TBL] [Abstract][Full Text] [Related]
15. Pyroptosis-Related lncRNA Prognostic Model for Renal Cancer Contributes to Immunodiagnosis and Immunotherapy.
Zhou X; Yao L; Zhou X; Cong R; Luan J; Wei X; Zhang X; Song N
Front Oncol; 2022; 12():837155. PubMed ID: 35860590
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a novel DNA damage repair-related long non-coding RNA signature in predicting prognosis, immunity, and drug sensitivity in uterine corpus endometrial carcinoma.
Wang T; Ji M; Liu W; Sun J
Comput Struct Biotechnol J; 2023; 21():4944-4959. PubMed ID: 37876625
[TBL] [Abstract][Full Text] [Related]
17. Identification of methylation-driven genes prognosis signature and immune microenvironment in uterus corpus endometrial cancer.
Liu J; Ji C; Wang Y; Zhang C; Zhu H
Cancer Cell Int; 2021 Jul; 21(1):365. PubMed ID: 34246261
[TBL] [Abstract][Full Text] [Related]
18. A novel risk prediction model of pyroptosis-related genes for the prognosis and immunotherapy response of endometrial cancer.
Liu ZS; Jing CL
Eur Rev Med Pharmacol Sci; 2022 Apr; 26(7):2259-2278. PubMed ID: 35442481
[TBL] [Abstract][Full Text] [Related]
19. Identification of an immune gene signature for predicting the prognosis of patients with uterine corpus endometrial carcinoma.
Zhou C; Li C; Yan F; Zheng Y
Cancer Cell Int; 2020 Nov; 20(1):541. PubMed ID: 33292199
[TBL] [Abstract][Full Text] [Related]
20. Identification of the Prognostic Signature Associated With Tumor Immune Microenvironment of Uterine Corpus Endometrial Carcinoma Based on Ferroptosis-Related Genes.
Liu J; Wang Y; Meng H; Yin Y; Zhu H; Ni T
Front Cell Dev Biol; 2021; 9():735013. PubMed ID: 34692692
[No Abstract] [Full Text] [Related]
[Next] [New Search]
